AVE 1625

Pricing Availability   Qty
Cat.No. 6763 - AVE 1625 | C23H20Cl2F2N2O2S | CAS No. 358970-97-5
Description: Potent and selective CB1 receptor antagonist
Alternative Names: Drinabant
Chemical Name: N-[1-[Bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-(3,5-difluorophenyl)methanesulfonamide
Purity: ≥98% (HPLC)
Datasheet
Citations
Reviews
Literature

Biological Activity

Potent and selective CB1 receptor antagonist (IC50 values are 25 and 10 nM for human and rat CB1R, respectively). Exhibits >400-fold selectivity for CB1 over CB2 receptors. Attenuates Olanzapine (Cat. No. 4349) induced weight gain and food intake in rats with no effect on energy expenditure or motility. Also improves cognitive function in rodent schizophrenia models and ameliorates extrapyramidal side-effects of antipsychotics.

Technical Data

M. Wt 497.38
Formula C23H20Cl2F2N2O2S
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 358970-97-5
PubChem ID 10278470
InChI Key IQQBRKLVEALROM-UHFFFAOYSA-N
Smiles CS(=O)(N(C1=CC(F)=CC(F)=C1)C2CN(C(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl)C2)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 49.74 100

Preparing Stock Solutions

The following data is based on the product molecular weight 497.38. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.01 mL 10.05 mL 20.11 mL
5 mM 0.4 mL 2.01 mL 4.02 mL
10 mM 0.2 mL 1.01 mL 2.01 mL
50 mM 0.04 mL 0.2 mL 0.4 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service

References

References are publications that support the biological activity of the product.

Herling et al (2007) CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am.J.Physiol.Endocrinol.Metab. 293 E826 PMID: 17595216

Liebig et al (2010) Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625. Obesity 18 1952 PMID: 20168311

Black et al (2011) AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology (Berl.) 215 149 PMID: 21181124


If you know of a relevant reference for AVE 1625, please let us know.

View Related Products by Target

View Related Products by Product Action

View all CB1 Receptor Antagonists

Keywords: AVE 1625, AVE 1625 supplier, AVE1625, cannabinoid, receptor, antagonist, potent, selective, CB1, CB1R, anti-obesity, Drinabant, Receptors, 6763, Tocris Bioscience

Citations for AVE 1625

Citations are publications that use Tocris products.

Currently there are no citations for AVE 1625. Do you know of a great paper that uses AVE 1625 from Tocris? Please let us know.

Reviews for AVE 1625

There are currently no reviews for this product. Be the first to review AVE 1625 and earn rewards!

Have you used AVE 1625?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Neurodegeneration

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Pain

Pain Research Product Guide

A collection of over 250 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Cannabinoid Receptor Ligands

Cannabinoid Receptor Ligands Scientific Review

Written by Roger Pertwee, this review discusses compounds which affect the activity of the endocannabinoid system, focusing particularly on ligands that are most widely used as experimental tools and denotes compounds available from Tocris.

Addiction

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Schizophrenia

Schizophrenia Poster

Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.